留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

自体干细胞治疗克罗恩病疗效的meta分析

刘志威 赵利婷 何京 陈友鹏

刘志威, 赵利婷, 何京, 陈友鹏. 自体干细胞治疗克罗恩病疗效的meta分析[J]. 分子影像学杂志, 2019, 42(1): 99-103. doi: 10.12122/j.issn.1674-4500.2019.01.23
引用本文: 刘志威, 赵利婷, 何京, 陈友鹏. 自体干细胞治疗克罗恩病疗效的meta分析[J]. 分子影像学杂志, 2019, 42(1): 99-103. doi: 10.12122/j.issn.1674-4500.2019.01.23
Zhiwei LIU, Liting ZHAO, Jing HE, Youpeng CHEN. Meta-analysis of effect of autologous stem cells treatment on Crohn's disease[J]. Journal of Molecular Imaging, 2019, 42(1): 99-103. doi: 10.12122/j.issn.1674-4500.2019.01.23
Citation: Zhiwei LIU, Liting ZHAO, Jing HE, Youpeng CHEN. Meta-analysis of effect of autologous stem cells treatment on Crohn's disease[J]. Journal of Molecular Imaging, 2019, 42(1): 99-103. doi: 10.12122/j.issn.1674-4500.2019.01.23

自体干细胞治疗克罗恩病疗效的meta分析

doi: 10.12122/j.issn.1674-4500.2019.01.23
详细信息
    作者简介:

    刘志威,硕士,住院医师,E-mail: 843517495@qq.com;赵利婷,本科,住院医师,E-mail: litiing919@yeah.net。刘志威与赵利婷共同为第一作者

    通讯作者:

    陈友鹏,主任医师,教授,博士生导师,E-mail: youpeng.chen@163.com

Meta-analysis of effect of autologous stem cells treatment on Crohn's disease

  • 摘要: 目的 评价自体干细胞治疗对克罗恩病的疗效。 方法 检索 Pubmed、MEDLINE、EBSCO、Current Content Connect、Cochrane、中国生物医学文献数据库、中国知网、万方数据库、维普数据库、谷歌学术、全国图书馆参考咨询联盟等参考文献,检索年限1963年2月~2018年7月。由2位研究者独立进行数据搜集、评价纳入研究质量、进行资料提取及交叉核对后,对纳入的研究数据使用 RevMan 5.3 软件进行多因素分析,并进行Q检验鉴定研究间异质性, 根据Q检验结果分别采用随机效应和固定效应模型合并研究,同时根据统计项目的不同进行亚组分析。 结果 检索到相关论文共1048篇,排除动物实验、病例报道及个案,最终纳入13篇论文,其中9个回顾性研究、4个病例对照研究。荟萃分析表明,通过对单臂试验统计干细胞治疗前后总体病情缓解,共纳入9篇文献,分析总体人数与有效人数危险度差,经统计分析后干细胞治疗前后危险度差值有统计学意义(RD=0.81,P<0.00001)。通过进一步统计分析纳入文献经干细胞治疗前后OR值,差异有统计学意义(OR=11,P<0.00001),但克罗恩病疾病活动指数试验组与对照组差异无统计学意义(P=0.13)。 结论 自体干细胞治疗短期内可减轻克罗恩病患者临床症状,但其安全性及其疗效确切性,有待于进一步明确。

     

  • 图  2  纳入文献危险度差分析

    图  1  文献筛选流程

    图  4  治疗前纳入文献CDAI指数分析

    图  3  纳入文献OR值分析

    表  1  纳入试验质量评价

    研究名称 选择性 可比性 暴露分析
    病例定义充分性 病例代表性 对照的选择 对照的定义 暴露的确定 是否采用相同确定方法 无应答率相同
    Hawkey 2015 1 1 0 0 1 1 1 0
    Julián Panés 2016 1 1 0 1 1 1 1 1
    Jian Zhang2018 1 1 0 0 1 1 1 0
    Julián Panés2018 1 1 0 1 1 1 1 0
    下载: 导出CSV
  • [1] Baumgart DC, Sandborn WJ. Crohn's disease[J]. Lancet, 2012, 380(9853): 1590-605 doi: 10.1016/S0140-6736(12)60026-9
    [2] Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review[J]. Gastroenterology, 2012, 142(1): 46-54 doi: 10.1053/j.gastro.2011.10.001
    [3] 李冠炜, 任建安. 重视我国克罗恩病流行病学的研究[J]. 肠外与肠内营养, 2017, 24(3): 135-7
    [4] Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease[J]. Gastroenterology, 2011, 140(6): 1704-12 doi: 10.1053/j.gastro.2011.02.046
    [5] 陈灏珠, 钟南山, 陆再英, 等. 内科学[M]. 9版. 北京: 卫生出版社, 2018.
    [6] Lopez-Cubero SO, Sullivan KM, Mcdonald GB. Course of crohn's disease after allogeneic marrow transplantation[J]. Gastroenterology, 1998, 114(3): 433-40 doi: 10.1016/S0016-5085(98)70525-6
    [7] Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone Marrow-Derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with crohn's disease[J]. Gastroenterology, 2015, 149(4): 918-27 doi: 10.1053/j.gastro.2015.06.014
    [8] Becker AJ, Till JE, Mcculloch EA. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells[J]. Nature, 1963, 197(486): 452-4
    [9] Lichtenstein GR, Loft J, Isaacs KL, et al. ACG clinical guideline: management of crohn's disease in adults[J]. Am J Gastroenterol, 2018, 113(4): 481-517 doi: 10.1038/ajg.2018.27
    [10] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-5 doi: 10.1007/s10654-010-9491-z
    [11] Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoetic stem cell transplantation for refractory crohn disease a randomized clinical trial[J]. JAMA, 2015, 314(23): 2524-34 doi: 10.1001/jama.2015.16700
    [12] Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial[J]. Lancet, 2016, 388(151): 1281-90
    [13] Panes J, Garcia-Olmo D, Van Assche G, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with crohn's disease[J]. Gastroenterology, 2018, 154(5): 1334-8 doi: 10.1053/j.gastro.2017.12.020
    [14] Zhang J, Lv S, Liu X, et al. Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial[J]. Gut Liver, 2018, 12(1): 73-9 doi: 10.5009/gnl17035
    [15] Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell transplantation without CD34(+) cell selection in refractory Crohn's disease[J]. Gut, 2008, 57(2): 211-7 doi: 10.1136/gut.2007.128694
    [16] 陈隆典, 欧阳建, 张晓琦. 自体造血干细胞移植治疗难治性炎症性肠病10例回顾与随访[J]. 中华消化杂志, 2008, 28(7): 476-9 doi: 10.3760/j.issn:0254-1432.2008.07.014
    [17] Garcia-Olmo D, Herreros D, Pascual MA, et al. Treatment of enterocutaneous fistula in Crohn's disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion[J]. Int J Colorectal Dis, 2009, 24(1): 27-30 doi: 10.1007/s00384-008-0559-0
    [18] de la Portilla F, Alba F, García-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial[J]. Int J Colorectal Dis, 2013, 28(3): 313-23 doi: 10.1007/s00384-012-1581-9
    [19] Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease[J]. Gut, 2011, 60(6): 788-98 doi: 10.1136/gut.2010.214841
    [20] Lee WY, Park KJ, Cho YB, et al. Autologous adipose Tissue-Derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for crohn's fistula[J]. Stem Cells, 2013, 31(11): 2575-81 doi: 10.1002/stem.v31.11
    [21] Cho YB, Lee WY, Park KJ, et al. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study[J]. Cell Transplant, 2013, 22(2): 279-85 doi: 10.3727/096368912X656045
    [22] Cho YB, Park KJ, Yoon SN, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn's fistula[J]. Stem Cells Transl Med, 2015, 4(5): 532-7 doi: 10.5966/sctm.2014-0199
    [23] Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease[J]. Gastroenterology, 2005, 128(3): 552-63 doi: 10.1053/j.gastro.2004.11.051
    [24] Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays[J]. Cell Stem Cell, 2008, 2(4): 313-9 doi: 10.1016/j.stem.2008.03.002
    [25] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells[J]. Science, 1999, 284(5411): 143-7 doi: 10.1126/science.284.5411.143
    [26] Cho PS, Messina DJ, Hirsh EL, et al. Immunogenicity of umbilical cord tissue-derived cells[J]. Blood, 2008, 111(1): 430-8 doi: 10.1182/blood-2007-03-078774
    [27] 陈月红, 杜 亮, 耿兴远, 等. 无对照二分类数据的Meta分析在RevMan软件中的实现[J]. 中国循证医学杂志, 2014, 14(7): 889-96
    [28] Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with crohn's disease[J]. Gastroenterology, 2017, 153(1): 59-64 doi: 10.1053/j.gastro.2017.04.001
    [29] Ciccocioppo R, Corazza GR. Mesenchymal stem cells for fistulising Crohn's disease[J]. Lancet, 2016, 388(151): 1251-2
    [30] 谢明颢, 何晓生, 朱金玲, 等. 脂肪来源间充质干细胞治疗克罗恩病的实验研究[J]. 中华胃肠外科杂志, 2015, 17(1): 58-64 doi: 10.3760/cma.j.issn.1671-0274.2015.01.015
    [31] Wang M, Liang C, Hu H, et al. Intraperitoneal injection (IP), Intravenous injection (IV) or anal injection (AI)? Best way for mesenchymal stem cells transplantation for colitis[J]. Sci Rep, 2016, 6(18): 30696-703
    [32] Qiu X, Feng JR, Chen LP, et al. Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn's disease: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2017, 96(26): e7381-7 doi: 10.1097/MD.0000000000007381
    [33] Qiu Y, Li MY, Feng T, et al. Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn's disease[J]. Stem Cell Res Ther, 2017, 8(1): 136-42 doi: 10.1186/s13287-017-0570-x
  • 加载中
图(4) / 表(1)
计量
  • 文章访问数:  896
  • HTML全文浏览量:  443
  • PDF下载量:  29
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-09-30
  • 刊出日期:  2019-01-01

目录

    /

    返回文章
    返回

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者:

    为了缩短出版时滞,促进科研成果的快速传播,我刊自2024年1月起,刊期由双月刊变更为月刊。本刊主要栏目有:基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱!

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日